Kristen Ganjoo

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi Antiangiogenesis agents in the treatment of soft tissue sarcomas
    Kristen Ganjoo
    Division of Oncology, Stanford University, Palo Alto, CA, USA
    Cancer 116:1177-83. 2010
  2. ncbi Current and emerging pharmacological treatments for gastrointestinal stromal tumour
    Kristen N Ganjoo
    Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, Stanford, California, USA
    Drugs 71:321-30. 2011
  3. ncbi New developments in targeted therapy for soft tissue sarcoma
    Kristen N Ganjoo
    Stanford University, 269 Campus Drive, Stanford, CA 94305, USA
    Curr Oncol Rep 12:261-5. 2010
  4. ncbi A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
    Kristen N Ganjoo
    Stanford University Medical Center, Stanford, Calif, USA
    Oncology 80:50-6. 2011
  5. ncbi Trabectedin: an anticancer drug from the sea
    Kristen N Ganjoo
    Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Expert Opin Pharmacother 10:2735-43. 2009
  6. ncbi The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients
    Kristen N Ganjoo
    Division of Oncology, Stanford University, Stanford, CA, USA
    J Cancer Res Clin Oncol 134:381-7. 2008
  7. ncbi Non-Hodgkin lymphoma of the breast
    Kristen Ganjoo
    Department of Medical Oncology, Stanford University, Stanford, California, USA
    Cancer 110:25-30. 2007
  8. ncbi Antiangiogenesis: a new approach to the treatment of lymphoma
    Kristen Ganjoo
    Department of Medicine (Oncology, Stanford University, Palo Alto, CA 94304, USA
    Leuk Lymphoma 48:454-5. 2007
  9. ncbi Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis
    Kristen N Ganjoo
    Department of Medicine Oncology, Stanford University, CA, USA
    Leuk Lymphoma 47:998-1005. 2006
  10. ncbi Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer
    Jonathan W Riess
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
    Cancer Invest 30:231-5. 2012

Detail Information

Publications16

  1. ncbi Antiangiogenesis agents in the treatment of soft tissue sarcomas
    Kristen Ganjoo
    Division of Oncology, Stanford University, Palo Alto, CA, USA
    Cancer 116:1177-83. 2010
    ..In addition, the authors conducted an in-depth review of the results from using key antiangiogenesis agents in the treatment of STS...
  2. ncbi Current and emerging pharmacological treatments for gastrointestinal stromal tumour
    Kristen N Ganjoo
    Department of Medicine, Division of Oncology, Stanford Comprehensive Cancer Center, Stanford, California, USA
    Drugs 71:321-30. 2011
    ..The duration of adjuvant therapy is currently under evaluation; however, it is possible that these patients would need to continue therapy indefinitely...
  3. ncbi New developments in targeted therapy for soft tissue sarcoma
    Kristen N Ganjoo
    Stanford University, 269 Campus Drive, Stanford, CA 94305, USA
    Curr Oncol Rep 12:261-5. 2010
    ....
  4. ncbi A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma
    Kristen N Ganjoo
    Stanford University Medical Center, Stanford, Calif, USA
    Oncology 80:50-6. 2011
    ..Patients and..
  5. ncbi Trabectedin: an anticancer drug from the sea
    Kristen N Ganjoo
    Stanford University, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Expert Opin Pharmacother 10:2735-43. 2009
    ..Trabectedin (ET-743) is an anticancer agent originally isolated from Ecteinascidia turbinata, a marine organism...
  6. ncbi The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients
    Kristen N Ganjoo
    Division of Oncology, Stanford University, Stanford, CA, USA
    J Cancer Res Clin Oncol 134:381-7. 2008
    ..This is a single institution retrospective study evaluating the role of angiogenesis markers in the clinical outcome of patients with diffuse large B cell lymphoma (DLBCL)...
  7. ncbi Non-Hodgkin lymphoma of the breast
    Kristen Ganjoo
    Department of Medical Oncology, Stanford University, Stanford, California, USA
    Cancer 110:25-30. 2007
    ..A retrospective study was done to evaluate the institutional experience in this patient population...
  8. ncbi Antiangiogenesis: a new approach to the treatment of lymphoma
    Kristen Ganjoo
    Department of Medicine (Oncology, Stanford University, Palo Alto, CA 94304, USA
    Leuk Lymphoma 48:454-5. 2007
  9. ncbi Rituximab, bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: safety, biomarker and pharmacokinetic analysis
    Kristen N Ganjoo
    Department of Medicine Oncology, Stanford University, CA, USA
    Leuk Lymphoma 47:998-1005. 2006
    ..In this patient population, treatment with RA-CHOP did not result in any episodes of grade 3 or 4 proteinuria, heart failure or hemorrhage. The RA-CHOP combination was generally well tolerated and safe...
  10. ncbi Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer
    Jonathan W Riess
    Division of Hematology, Department of Medicine, Stanford University School of Medicine, CA, USA
    Cancer Invest 30:231-5. 2012
    ..268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients...
  11. ncbi Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study
    Brad S Kahl
    Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Cancer 116:106-14. 2010
    ..Bendamustine hydrochloride is a novel alkylating agent. In this multicenter study, the authors evaluated the efficacy and toxicity of single-agent bendamustine in patients with rituximab-refractory, indolent B-cell lymphoma...
  12. ncbi A phase II first-line study of gemcitabine, carboplatin, and bevacizumab in advanced stage nonsquamous non-small cell lung cancer
    Christelle Clément-Duchêne
    Division of Oncology, Department of Medicine, Department of Biostatistics, Stanford Cancer Center, Stanford University, Stanford, California 94305 5826, USA
    J Thorac Oncol 5:1821-5. 2010
    ..This study was designed to evaluate toxicities and efficacy of gemcitabine/carboplatin/bevacizumab...
  13. ncbi Breast Angiosarcoma: Case Series and Expression of Vascular Endothelial Growth Factor
    Rondeep Brar
    Department of Internal Medicine, Stanford University Medical Center, Stanford, Calif, USA
    Case Rep Oncol 2:242-250. 2009
    ..CONCLUSION: Angiosarcoma of the breast is an aggressive malignancy with a propensity for both local recurrence and distant metastases. Angiogenesis inhibition may represent a novel therapeutic modality in this rare, vascular malignancy...
  14. ncbi Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome
    Eve Henry
    Department of Medicine, Stanford University, Stanford, California, USA
    J Natl Compr Canc Netw 10:939-42. 2012
    ....
  15. ncbi 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma
    Andrei Iagaru
    Division of Nuclear Medicine, Stanford University Medical Center, 300 Pasteur Drive, Stanford, CA 94305, USA
    Mol Imaging Biol 12:198-203. 2010
    ..Both target CD20 receptors present on the surface of lymphocytes. We present our clinical experience with Bexxar and Zevalin in the management of low-grade refractory or relapsed NHL...
  16. ncbi Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia
    Arthur E Frankel
    Department of Medicine, Scott and White Hospital, Temple, Texas 76508, USA
    Cancer 106:2158-64. 2006
    ....